The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results